Consolidated Statements of Income Pfizer Inc. and Subsidiary Companies Year Ended December 31, 2020 2019 2018 41,908 $ 41,172 $ 40,825 $ 8,987 12,612 7,760 4,736 1,058 (MILLIONS, EXCEPT PER COMMON SHARE DATA) Revenues Costs and expenses: Cost of sales Selling, informational and admilostrative expenses Research and development expenses Amortization of intangible assets Restructuring charges and certain acquisition-related costs (Gain) on completion of Consumer Healthcare JV transaction Other (incomey deductions--net Income from continuing operations before provision/(benefit) for taxes on income Provision/(benefit) for taxes on income Income from continuing operations Income from discontinued operations.net of tax Net Income before allocation to noncontrolling interests Less: Net Income attributable to noncontrolling interests Net income attributable to Pfizer Inc, common shareholders Earings per common share basic: Income from continuing operations attributable to Pfizer Inc common shareholders Income from discontinued operations--net of tax Net income attributable to Pfizer Inc. common shareholders Earnings per common share-diluted: Income from continuing operations attributable to Pfizer Inc. common shareholders Income from discontinued operations--net of tax Net income attributable to Pfizer Inc. common shareholders Weighted-average shares-basio Weighted average shares-diluted 8,692 11,615 9,405 3,436 600 (6) 669 7,497 477 7,021 2,631 9,652 36 9,616 $ 8,251 12,750 8,394 4,462 601 (8,086) 3,314 11,485 618 10,867 5,435 16,302 29 16,273 $ 2,077 3,594 (266) 3,861 7,328 11,188 36 11 153 $ 1.26 $ 0.47 1.73 $ 1.95$ 0.98 2.92 $ 0.65 1.25 1.90 $ $ 1.24 $ 0.47 1.91 $ 0.96 2.87 $ 0.64 1.23 1.87 $ 1.71 $ 5,555 5,632 5,569 5,675 5,872 5,977 1.) Complete Horizontal analysis of Statement of Income